in vivo studies

Attentive Science is a contract research organization (CRO) providing preclinical research and laboratory services, including pharmacokinetics, regulatory toxicology, and safety pharmacology studies. The company states its services are designed for companies developing cures and remedies, and it is located in Stilwell, Kansas, United States.

GLP studiespharmacokinetics testingregulatory toxicologysafety pharmacologystudy reporting

Burleson Research Technologies (BRT) is a contract research organization specializing in immune safety, immunotoxicology, and preclinical efficacy research for pharmaceutical, biotechnology, chemical, and medical device organizations. Founded in 1996 by Drs. Gary and Florence Burleson, BRT provides customized preclinical research programs integrating in vivo, in vitro, ex vivo, and bioanalytical capabilities. The company operates an approximately 10,000-square-foot facility in Morrisville, North Carolina, near Research Triangle Park.

bioanalytical assayscell-based assayscustomized study designex vivo assessmentshost resistance modelshumanized and immunocompromised mouse modelshypersensitivity modelsimmunogenicity testingimmunotoxicity testingin vitro assaystumor models

ChemDiv is a fully integrated target-to-clinic contract research organization (CRO) that has worked for over 32 years on drug discovery programs for cancer, neurological, infectious, cardiometabolic and immune diseases with pharma, biotech and academic partners. It offers integrated drug discovery services including custom chemistry, HTS, CADD, ADME, DMPK, discovery biology and preclinical services.

ADME/DMPK testinganimal modelscombinatorial chemistrycustom chemistryhigh throughput screening (HTS)in silico drug design (CADD)in vitro assayslibrary designmedicinal chemistrymolecular dockingmolecular dynamicspharmacokinetic studiestoxicology studiesvirtual screening

Dauntless Biotherapeutics is a private preclinical oncology company led and advised by a team of researchers and industry veterans. It is developing an Antibody Drug Conjugate (ADC) to an undisclosed Tumor Associated Antigen (TAA) to treat cancers of unmet need, and is conducting a seed round to raise capital for lead optimization, in vivo, and non-GLP toxicity studies in preparation of an IND filing.

IND filing preparationlead optimizationnon-GLP toxicity studies

ETAP-LAB is an independent preclinical CRO providing efficacy testing and preclinical pharmacology services to pharmaceutical, biotechnology and nutraceutical industries. Its services support drug discovery from in vitro lead optimization to non-GLP animal testing (POC, PK/PD, non-regulatory safety pharmacology) to assess efficacy and safety of drug candidates, medical devices and nutraceuticals. It has over 35 years of experience and is ISO 9001 certified (Nancy and Caen).

animal housingbrain-on-chiphigh content imaginghistologyimmunoassaysimmunofluorescenceimmunohistochemistryin vitro testinglead optimizationmicrofluidicsPK/PDPOCpreclinical medical imagingpreclinical pharmacologysafety pharmacology

FAKnostics is a biopharmaceutical company developing therapeutics and diagnostics based on its Focal Adhesion Kinase (FAK) platform technology to combat metastatic cancers and fibrosis. Its proprietary hydrocarbon-stapled peptide FN-2012 blocks the FAK FAT domain, and its FAKnosTEST companion diagnostic detects cancer in early stages. The company reports more than 30 years of FAK research leadership and has 3 pre-clinical programs in fibrotic diseases.

computational drug discoverydrug discoveryimmunohistochemical (IHC) diagnosticsin-vitro approachespharmacologystructure-based drug design

Forta Bio is a private, California-based biotech developing ODC™ (Oligonucleotide-Dependent Cytotoxicity), a therapeutic class it created to selectively eliminate pathogenic cells while aiming to preserve healthy immunity. Built on foundational research at City of Hope and supported by multi-million-dollar grant funding, its platform spans oncology (FortaOnc™), autoimmune disease (FortaReg™), and aptamer-targeted delivery (FortaApt™), supported by its internal screening and optimization engine FortaGuideAI.

aptamer-targeted deliverydrug developmentgenerative multi-objective optimizationhigh throughput screeningoligonucleotide therapeutics

Kimer Med is a New Zealand biotech company founded in 2020 and based in Nelson, developing a family of broad-spectrum antiviral therapeutics. Its proprietary platform enables rapid design and optimisation of antiviral drug candidates, with demonstrated efficacy against 24 viruses across 12 virus families in in vitro studies and positive early in vivo data. The company closed a NZ$14 million Series A round in October 2024 to support R&D toward Phase 1 trials.

antiviral drug design and optimisationdrug development toward Phase 1 trialsin vitro studies